Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Sarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Glioma 1Breast Neoplasms 1Advanced Cancers 1

Interventions

aldesleukin 42Sunitinib 39Cyclophosphamide 30Nivolumab 27Everolimus 27pembrolizumab 26Interferon-alpha 25Bevacizumab 22Sorafenib 21Interleukin-2 20fludarabine phosphate 19Filgrastim 18Ipilimumab 17Radiotherapy 16Axitinib 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14fludarabine 11Radiosurgery 11Doxorubicin 11Carboplatin 11temsirolimus 10Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8belzutifan 8atezolizumab 8Fluorouracil 8pazopanib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Kidney Neoplasms × AH 111585 × Clear all
NCT01633255 2019-12-17

[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Genitourinary

Kidney Neoplasms

NCT01961583 2016-03-01

[18F]Fluciclatide PET Imaging of Pazopanib Response

Asan Medical Center

Phase 2 Terminated
12 enrolled
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡